Novartis strikes about $7.8 billion mRNA deal with China's Abogen
02/10/2026 08:29
Novartis strikes about $7.8 billion mRNA deal with China's Abogen Oct 2 (Reuters) - Chinese biotech company Abogen said on Friday it signed a licensing and option agreement worth about $7.8 billion with Swiss drug maker Novartis NOVN.S to advance RNA-based therapy.
(Reporting by Ruchika Khanna in Bengaluru; Editing by Subhranshu Sahu)
Recent news on Novartis AG
See all newsEurope Research Roundup: Ambu, Intesa Sanpaolo, Solvay
Swiss pharma industry behind in technology and clinical trials, index shows
European shares rise as Democrats take US Congress, Novo Nordisk surges
European shares rise as Democratic sweep lifts clean energy, bank stocks
Europe set to open lower as Democratic sweep fuels AI regulation fears